Loading...
B

Burning Rock Biotech Ltd
NASDAQ:BNR

Watchlist Manager
Burning Rock Biotech Ltd
NASDAQ:BNR
Watchlist
Price: 2.9 USD -0.68% Market Closed
Updated: Mar 25, 2023

Intrinsic Value

The intrinsic value of one BNR stock under the Base Case scenario is 6.77 USD. Compared to the current market price of 2.9 USD, Burning Rock Biotech Ltd is Undervalued by 57%.

The Intrinsic Value is calculated as the average of the two valuation methods:

BNR Intrinsic Value
Base Case
6.77 USD
Undervaluation 57%
Intrinsic Value
Price
B
Worst Case
Base Case
Best Case

Fundamental Analysis

BNR Profitability Score
Profitability Due Diligence

Burning Rock Biotech Ltd's profitability score is 25/100. The higher the profitability score, the more profitable the company is.

Negative 3-Year Average ROE
Negative 3-Year Average ROIC
Negative Free Cash Flow
Negative Operating Income
25/100
Profitability
Score

Burning Rock Biotech Ltd's profitability score is 25/100. The higher the profitability score, the more profitable the company is.

BNR Solvency Score
Solvency Due Diligence

Burning Rock Biotech Ltd's solvency score is 49/100. The higher the solvency score, the more solvent the company is.

Low Interest Coverage
Low Altman Z-Score
Short-Term Liabilities
Long-Term Liabilities
49/100
Solvency
Score

Burning Rock Biotech Ltd's solvency score is 49/100. The higher the solvency score, the more solvent the company is.

Financials

Balance Sheet Decomposition
Burning Rock Biotech Ltd

Current Assets 1.4B
Cash & Short-Term Investments 1B
Receivables 149M
Other Current Assets 196M
Non-Current Assets 377M
Long-Term Investments 644k
PP&E 347M
Intangibles 2.8M
Other Non-Current Assets 26.4M
Current Liabilities 363M
Accounts Payable 71M
Accrued Liabilities 121M
Other Current Liabilities 171M
Non-Current Liabilities 68.9M
Other Non-Current Liabilities 68.9M
Efficiency
68%
Gross Margin
-179%
Operating Margin
-177%
Net Margin
-88%
FCF Margin
Other

BNR Capital Structure
Burning Rock Biotech Ltd

Market Capitalization 305M USD
Total Debt 0 USD
Minority Interest 0 USD
Preferred Equity 0 USD
Cash and Equivalents 1B USD
Short-Term Investments 0 USD
Enterprise Value -705M USD

Wall St
Price Targets

BNR Price Targets Summary
Burning Rock Biotech Ltd

Wall Street analysts forecast BNR stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for BNR is 6.95 USD with a low forecast of 3.84 USD and a high forecast of 11.34 USD.

Lowest
Price Target
3.84 USD
32% Upside
Average
Price Target
6.95 USD
140% Upside
Highest
Price Target
11.34 USD
291% Upside
View Analyst Estimates
View Analyst Estimates

Competitive Landscape

BNR Competitors
Burning Rock Biotech Ltd

BNR Suppliers & Customers
Burning Rock Biotech Ltd

Suppliers Map
Customers Map

Shareholder Return

BNR Return Decomposition
Main factors of price return

Price Return Decomposition
is not available

It is impossible to break down the market cap return as the net margin from 5 years ago is negative.

What is price return decomposition?

BNR Price
Burning Rock Biotech Ltd

1M 1M
-6%
6M 6M
+11%
1Y 1Y
-69%
3Y 3Y
-88%
5Y 5Y
-88%
Annual Price Range
2.9
52w Low
1.73
52w High
10.44
Price Metrics
Average Annual Return -29.45%
Standard Deviation of Annual Returns 40.61%
Max Drawdown -96%
Shares Statistics
Market Capitalization 305M USD
Shares Outstanding 105 725 500
Percentage of Shares Shorted 5.22%

Company Profile

Burning Rock Biotech Ltd

Country

China

Industry

Biotechnology

Market Cap

305M USD

Dividend Yield

0%

Description

Burning Rock Biotech Ltd. engages in the investment of medical fields. The company is headquartered in Guangzhou, Guangdong. The company went IPO on 2020-06-12. The firm operates three segments. Central Laboratory Business segment is engaged in the sales of cancer therapy selection test to individual patients. In-Hospital Business segment is engaged in the sales of reagent kits and the provision of the facilitation services for the sale of laboratory equipment to hospitals. Pharma Research and Development Services segment provide services to companies primarily in relation to the development of targeted therapies and immunotherapies for various types of cancer, and to hospitals for their studies on cancer diagnosis and treatment. Its products include OncoScreen Plus and LungPlasma. Its NGS-based cancer therapy selection tests applicable to a broad range of cancer types, including lung cancer, prostate cancer, breast cancer and others. The firm mainly conducts its businesses in the China market.

Contact

GUANGDONG
Guangzhou
No. 5 Xingdao Ring Road North,, International Bio Island
+8618501641666.0
http://www.brbiotech.com/

IPO

2020-06-12

Employees

938

Officers

Chief Scientific Officer & Director
Dr. Shaokun Chuai
Founder, Chairman & CEO
Mr. Yusheng Han
CFO, Compliance Officer & Director
Mr. Jinxiang Li
Chief Technology Officer
Dr. Zhihong Zhang
Sr. Advisor
Mr. Hao Liu

See Also

Similar Stocks
What is the Intrinsic Value of one BNR stock?

The intrinsic value of one BNR stock under the Base Case scenario is 6.77 USD.

Is BNR stock undervalued or overvalued?

Compared to the current market price of 2.9 USD, Burning Rock Biotech Ltd is Undervalued by 57%.